Budget impact analysis of Haemate- P as long-term prophylaxis and on-demand therapy for von Willebrand disease in Spain

Le résumé fourni par la source

Objectives A decision-analytic model was developed to assess the Spanish healthcare system budget impact associated with increased use of Haemate-P in individuals with von Willebrand disease.Methods The model considered long-term prophylaxis and on-demand treatment with each of three von Willebrand factor (vWF) replacement products (Haemate-P, Fanhdi, and Wilate). Two budget scenarios were considered: a status quo scenario (no changes in uptake of products/strategy) and an alternative scenario (increased Haemate-P uptake). The model estimated total product costs and other medical costs for each budget scenario annually over 3 years. Total budget impact was estimated by subtracting the costs for the status quo scenario from the costs for the alternative scenario.Results The alternative Haemate-P uptake scenario was estimated to save the Spanish healthcare system €5.64 million over 3 years. Cost savings were driven primarily by a reduction in vWF product costs (−€5.62 million) resulting from a reduction in vWF product use (−€4.80 million) and bleed reductions (−€0.82 million). In univariate and multiway deterministic sensitivity analyses, the alternative scenario remained cost-saving.Conclusion Haemate-P was found to be a cost-saving strategy, and increased use of Haemate-P over Fanhdi, and Wilate is expected to reduce overall costs to the healthcare system in Spain.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.